Adding to the debate on once-a-week versus once-every-3-weeks cisplatin dosing in concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer

Abstract

One of the most popular debates in locally advanced head and neck squamous cell carcinoma (LAHNSCC) is the optimal dose and schedule of cisplatin when combined with radical radiotherapy in the curative setting, both postoperatively and as definitive chemoradiotherapy (CRT). Hoping to settle this debate once and for all, we conducted a phase III randomized clinical trial to answer this question (1).